Report of Foreign Issuer (6-k)
April 24 2017 - 08:28AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
April 2017
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
24 West 40
th
Street, 8
th
Floor
New York, NY 10018
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On April 24, 2017, Akari Therapeutics, Plc,
(the “Company”) issued a press release announcing that it will present data from an interim analysis of its ongoing
Phase II trial of Coversin in paroxysmal nocturnal hemoglobinuria (PNH), as well as preclinical data for additional indications
and other opportunities, at its Research and Development Day on April 24, 2017. A copy of the press release is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
The information contained in this report
(including the exhibit hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form S-3,
File No. 333-207443, Form S-8 (No. 333-198109 and 333-207444), Registration Statement on Form F-3 File No. 333-198107, and the
Registration Statements on Post-Effective Amendments to Form F-1 on Form F-3 (333-185247, 333-187826 and 333-191880).
Exhibit No.
99.1
|
Press Release dated April 24, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Robert M. Shaw
|
|
|
Name:
|
Robert M. Shaw
|
|
|
General Counsel & Secretary
|
|
Date: April 24, 2017
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2023 to Mar 2024